Currently Viewing:
Newsroom
Currently Reading
Researchers Find Correlation Between Gut Microbiome and Immunotherapy Response in Melanoma
June 06, 2017 – Laura Joszt
What We're Reading: Taxing Employer Health Plans; Global Cancer Costs; Surviving an Overdose
June 02, 2017 – AJMC Staff
Bariatric Surgery Linked to Lower Risk of Female-Specific Cancers
May 31, 2017 – Christina Mattina
Ceritinib Approved as First Line for ALK-Positive Advanced NSCLC
May 30, 2017 – Surabhi Dangi-Garimella, PhD
Physical Activity, Healthy Diet Improve Survival in Colorectal Cancer: Study at ASCO
May 29, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: May 26, 2017
May 26, 2017
Ahead of ASCO, Kite Pharma Announces Priority Review of Its CAR-T Treatment
May 26, 2017 – Surabhi Dangi-Garimella, PhD
Physician-Patient Responsible for Ban on Power Morcellators, Dies
May 25, 2017 – Surabhi Dangi-Garimella, PhD
A First: FDA Approves Pembrolizumab for Tissue-Agnostic Indication
May 23, 2017 – Surabhi Dangi-Garimella, PhD

Researchers Find Correlation Between Gut Microbiome and Immunotherapy Response in Melanoma

Laura Joszt
Bacteria in the gut microbiome is associated with disease progression or delay in patients with metastatic melanoma who were treated with immunotherapy, according to a study presented at the 2017 American Society of Clinical Oncology Annual Meeting.
Bacteria in the gut microbiome is associated with disease progression or delay in patients with metastatic melanoma who were treated with immunotherapy, according to a study presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Researchers from The University of Texas MD Anderson Cancer Center studied fecal samples from 105 patients with immune checkpoint blockers and found that a greater diversity of bacteria in the gut microbiome was associated with a higher response rate to treatment and a longer progression-free survival.

“The microbiome appears to shape a patient’s response to cancer immunotherapy, which opens potential pathways to use it to assess a patient’s fitness for immunotherapy and to manipulate it to improve treatment,” study leader Jennifer Wargo, MD, associate professor of Surgical Oncology at MD Anderson, said in a statement.

The researchers conducted an analysis of the presence of 16S ribosomal RNA to identify bacteria and determine microbiome composition from fecal samples.

Patients with metastatic melanoma were treated with a PD-1 inhibitor and at the median time to follow-up of 242 days, more than half of patients with high microbiome diversity had not had disease progression. Meanwhile, patients with a lower microbiome diversity had a median progression-free survival (PFS) of just 188 days.

In addition to bacteria diversity, specific types of bacteria had an impact. More than half of patients with an abundance of F. prausnitzii had not reached median PFS.

Despite the findings, Wargo cautioned against people self-medicating with probiotics and other methods. There still needs to be a better understanding of the relationship between the microbiome and cancer treatment.

Wargo’s team is collaborating with the Parker Institute for Cancer Immunotherapy to develop the first immunotherapy-microbiome trial to potentially launch later this year. They are also conducting lab and mouse model research on the connection between bacteria and the immune system.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up